These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 32492594)

  • 1. Clinical use of vascular endothelial growth factor receptor inhibitors for the treatment of renal cell carcinoma.
    Li W; Feng C; Di W; Hong S; Chen H; Ejaz M; Yang Y; Xu TR
    Eur J Med Chem; 2020 Aug; 200():112482. PubMed ID: 32492594
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vascular endothelial growth factor (VEGF) and VEGF receptor inhibitors in the treatment of renal cell carcinomas.
    Roskoski R
    Pharmacol Res; 2017 Jun; 120():116-132. PubMed ID: 28330784
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sunitinib, sorafenib and mTOR inhibitors in renal cancer.
    Radulovic S; Bjelogrlic SK
    J BUON; 2007 Sep; 12 Suppl 1():S151-62. PubMed ID: 17935273
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vascular endothelial growth factor-targeted therapies in advanced renal cell carcinoma.
    Albiges L; Salem M; Rini B; Escudier B
    Hematol Oncol Clin North Am; 2011 Aug; 25(4):813-33. PubMed ID: 21763969
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sunitinib malate for the treatment of renal cell carcinoma.
    Wood L
    Expert Opin Pharmacother; 2012 Jun; 13(9):1323-36. PubMed ID: 22607009
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of second-generation VEGFR tyrosine kinase inhibitors: current status.
    Bhargava P; Robinson MO
    Curr Oncol Rep; 2011 Apr; 13(2):103-11. PubMed ID: 21318618
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Progress and contrasts of the development of tivozanib for therapy of kidney cancer.
    Gupta S; Fishman M
    Expert Opin Pharmacother; 2011 Dec; 12(18):2915-22. PubMed ID: 22098229
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The progression free survival-plateau with vascular endothelial growth factor receptor inhibitors--is there more to come?
    Grünwald V; Merseburger AS
    Eur J Cancer; 2013 Jul; 49(11):2504-11. PubMed ID: 23601669
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improvement in survival end points of patients with metastatic renal cell carcinoma through sequential targeted therapy.
    Calvo E; Schmidinger M; Heng DY; Grünwald V; Escudier B
    Cancer Treat Rev; 2016 Nov; 50():109-117. PubMed ID: 27664394
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimizing treatment of renal cell carcinoma with VEGFR-TKIs: a comparison of clinical pharmacology and drug-drug interactions of anti-angiogenic drugs.
    Fogli S; Porta C; Del Re M; Crucitta S; Gianfilippo G; Danesi R; Rini BI; Schmidinger M
    Cancer Treat Rev; 2020 Mar; 84():101966. PubMed ID: 32044644
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted therapy for advanced renal cell cancer (RCC): a Cochrane systematic review of published randomised trials.
    Coppin C; Kollmannsberger C; Le L; Porzsolt F; Wilt TJ
    BJU Int; 2011 Nov; 108(10):1556-63. PubMed ID: 21952069
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emerging oral VEGF inhibitors for the treatment of renal cell carcinoma.
    Stitzlein L; Rao P; Dudley R
    Expert Opin Investig Drugs; 2019 Feb; 28(2):121-130. PubMed ID: 30572736
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Axitinib in the treatment of renal cell carcinoma: design, development, and place in therapy.
    Bellesoeur A; Carton E; Alexandre J; Goldwasser F; Huillard O
    Drug Des Devel Ther; 2017; 11():2801-2811. PubMed ID: 29033542
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of everolimus in patients with advanced renal cell carcinoma refractory or intolerant to VEGFR-TKIs and safety compared with prior VEGFR-TKI treatment.
    Kato R; Obara W; Matsuura T; Kato Y; Iwasaki K; Fujioka T
    Jpn J Clin Oncol; 2014 May; 44(5):479-85. PubMed ID: 24688083
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cabozantinib for the treatment of renal cell carcinoma.
    Escudier B; Lougheed JC; Albiges L
    Expert Opin Pharmacother; 2016 Dec; 17(18):2499-2504. PubMed ID: 27835047
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pazopanib: a multikinase inhibitor with activity in advanced renal cell carcinoma.
    Bukowski RM
    Expert Rev Anticancer Ther; 2010 May; 10(5):635-45. PubMed ID: 20469994
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Avelumab and axitinib combination therapy for the treatment of advanced renal cell carcinoma.
    Soleimani M; Nappi L; Kollmannsberger C
    Future Oncol; 2020 Dec; 16(36):3021-3034. PubMed ID: 32856478
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Profile of tivozanib and its potential for the treatment of advanced renal cell carcinoma.
    Cowey CL
    Drug Des Devel Ther; 2013; 7():519-27. PubMed ID: 23818763
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of tivozanib in advanced renal cell carcinoma therapy.
    Escudier B; Porta C; Eisen T; Belsey J; Gibson D; Morgan J; Motzer R
    Expert Rev Anticancer Ther; 2018 Nov; 18(11):1113-1124. PubMed ID: 30084668
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting vascular endothelial growth factor (VEGF)-receptor-signaling in renal cell carcinoma.
    Reuter CW; Morgan MA; Grünwald V; Herrmann TR; Burchardt M; Ganser A
    World J Urol; 2007 Mar; 25(1):59-72. PubMed ID: 17340158
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.